Clinical outcomes after immune checkpoint inhibitor-associated acute kidney injury: a cohort study
Individuals with ICPi-AKI are associated with an increased risk of all-cause mortality, MAKE and MACE. Enhancing awareness and timely intervention for ICPi-AKI are crucial for improving prognosis and reducing complications among patients with cancer.
Authors
- Heng‐Chih Pan (ORCID: https://orcid.org/0000-0001-5782-7138)
- Hong-Min Lin (ORCID: https://orcid.org/0000-0002-5335-2291)
- Ting-Ya Yang (ORCID: https://orcid.org/0000-0002-7323-9325)
- Vin‐Cent Wu (ORCID: https://orcid.org/0000-0001-7935-0991)
- Jui‐Yi Chen (ORCID: https://orcid.org/0000-0003-1376-7780)
- Min‐Hsiang Chuang (ORCID: https://orcid.org/0000-0002-8538-4861)
- Y.‐J. Chou
Institutions
- Min-Hwei College of Health Care Management (TW)
- Keelung Chang Gung Memorial Hospital (TW)
- National Taiwan University Hospital (TW)
- Chi Mei Medical Center (TW)
- Chia Nan University of Pharmacy and Science (TW)
Publication Details
- Journal
- BMJ Open
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1136/bmjopen-2024-092752
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05